pursuant to regulation 30 & 33 of Securities and Exchange Board of India, LODR, the Board of Directors at its meeting held on 11th August, 2025 have approved the unaudted financial result ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.0 pts more than Nifty Microcap 250 and 10.0 pts more than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Pentokey Organy reported a sharp jump in business activity for Q1 FY26. Revenue from operations rose to ₹506.20 lakhs, compared with just ₹60.62 lakhs in Q4 FY25 and only ₹0.00 lakhs in Q1 FY25; full-year FY25 revenue was ₹82.62 lakhs. Total income stood at ₹510.20 lakhs against total expenses of ₹461.73 lakhs, yielding a pre-tax and post-tax profit of ₹48.47 lakhs versus ₹4.60 lakhs in the year-ago quarter. Basic and diluted EPS came in at ₹0.99, up from ₹0.07 a year earlier. Total comprehensive income for the quarter was ₹62.19 lakhs, while reserves stood at ₹318.46 lakhs. The statutory auditor (Verma Mehta & Associates) issued an unmodified limited review report, and results pertain to the company's pharma/pesticides trading segment. A pending income tax demand of ₹171.58 lakhs for AY 2015-16, under appeal, was disclosed.
This is a strong quarter on paper — revenue and profit have multiplied several times over year-ago and sequential levels, which should be viewed positively by shareholders. However, the very low base and the lumpy nature of trading revenue (Q1 FY25 had near-zero revenue) mean investors should watch whether this scale of business is sustained in coming quarters before drawing firm conclusions.